Last reviewed 2026-05-18 · How we verify

EGCG, FA, HA, B12

Centro di Ricerca Clinica Salentino · Phase 2 active Small molecule Quality 10/100

EGCG, FA, HA, B12 is a Nutritional supplement combination Small molecule drug developed by Centro di Ricerca Clinica Salentino. It is currently in Phase 2 development. Also known as: Pervistop.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EGCG, FA, HA, B12
Also known as	Pervistop
Sponsor	Centro di Ricerca Clinica Salentino
Drug class	Nutritional supplement combination
Modality	Small molecule
Phase	Phase 2

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EGCG, FA, HA, B12 CI brief — competitive landscape report
EGCG, FA, HA, B12 updates RSS · CI watch RSS
Centro di Ricerca Clinica Salentino portfolio CI

Frequently asked questions about EGCG, FA, HA, B12

What is EGCG, FA, HA, B12?

EGCG, FA, HA, B12 is a Nutritional supplement combination drug developed by Centro di Ricerca Clinica Salentino.

Who makes EGCG, FA, HA, B12?

EGCG, FA, HA, B12 is developed by Centro di Ricerca Clinica Salentino (see full Centro di Ricerca Clinica Salentino pipeline at /company/centro-di-ricerca-clinica-salentino).

Is EGCG, FA, HA, B12 also known as anything else?

EGCG, FA, HA, B12 is also known as Pervistop.

What drug class is EGCG, FA, HA, B12 in?

EGCG, FA, HA, B12 belongs to the Nutritional supplement combination class. See all Nutritional supplement combination drugs at /class/nutritional-supplement-combination.

What development phase is EGCG, FA, HA, B12 in?

EGCG, FA, HA, B12 is in Phase 2.

Drug class: All Nutritional supplement combination drugs
Manufacturer: Centro di Ricerca Clinica Salentino — full pipeline
Also known as: Pervistop

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing